Compare CMCM & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMCM | HURA |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | China | United States |
| Employees | N/A | 22 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4M | 141.4M |
| IPO Year | 2014 | N/A |
| Metric | CMCM | HURA |
|---|---|---|
| Price | $3.36 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 25.4K | ★ 453.3K |
| Earning Date | 06-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.32 | $0.41 |
| 52 Week High | $9.44 | $3.90 |
| Indicator | CMCM | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 28.42 | 60.17 |
| Support Level | N/A | $2.38 |
| Resistance Level | $7.15 | $2.68 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 11.39 | 99.89 |
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The companies products and services includes Robotic Products, Global to B Services etc. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.